Background/Aims: Non-small cell lung cancer (NSCLC) is one of the deadliest cancers worldwide. Dopamine receptor D2 (DRD2) has multiple roles in clinical progression of NSCLC and functional maintenance of cancer cells. However, little is known about the molecular mechanism. Here, we clarified whether DRD2 inhibits lung cancer progression and identified the underlying downstream signaling. Methods: DRD2 mRNA and protein levels were detected in clinical specimens by qRT-PCR and immunohistochemistry, respectively. MTT and colony formation assays were applied to analyze cell proliferation. The underlying molecular mechanism was identified by dual luciferase, western blot, qRT-PCR, cAMP detection, immunoprecipitation, and chromatin immunoprecipitation assays. A murine NSCLC model was used to clarify the role of DRD2 in tumor cell proliferation. Results: We found that DRD2 ablated tumor cell growth. DRD2 expression in NSCLC tissues was lower than in adjacent normal lung tissues. Moreover, DRD2 mRNA and protein levels in NSCLC were negatively correlated with the tumor size, TNM status, and patient overall survival. In vitro experiments showed that disruption of DRD2 promoted the proliferation of NSCLC cell lines A549 and SK-MES-1 by inhibiting the NF-κB signaling pathway. Furthermore, DRD2 overexpression not 
Introduction
Lung cancer is the leading cause of cancer-related mortality worldwide, and non-small cell lung cancer (NSCLC) comprises approximately ~85% of lung cancers [1, 2] . Despite increasing advances focusing on the diagnosis and treatment of NSCLC subsets, improvement in the majority of patients has been very modest. In fact, the overall 5-year survival rate of NSCLC patients is still less than 20% [1] . Recently, emerging immunotherapies for this recurrent cancer have gained attention [3, 4] . Differing from traditional therapies including chemotherapy, radiotherapy, and their combinations with angiogenesis inhibitors, immunotherapies primarily target the rapidly dividing tumor cells by affecting key molecular events that drive tumor cell growth and invasion. Therefore, identifying the key molecular mechanisms underlying NSCLC progression is urgently needed to determine therapeutic targets for this disease.
Dopamine receptors (DRD1-5) mainly reside in the human brain, which play important roles in cancer tumorigenesis and progression [5] [6] [7] [8] [9] . DRD2 agonists inhibit the growth of lung cancer cells including NSCLC and small cell lung cancer [6, 10, 11] . Recently, DRD2 was found to be highly expressed in CD133+ adenocarcinoma NSCLC cells, and activation of DRD2 inhibited their proliferation, clonogenic ability, and invasiveness by suppressing extracellular signal-regulated kinases 1/2 and AKT, which was accompanied by downregulation of octamer-binding transcription factor 4 expression and matrix metalloproteinase-9 secretion [7] . Thus, DRD2 has multiple roles in NSCLC, and the biological functions of DRD2 in NSCLC cells, especially the underlying mechanisms, require further study.
The NF-κB signaling pathway is a well-studied pathway that induces expression of more than 200 genes involved in diverse processes including cell survival, adhesion, differentiation, and inflammation [12] . Activation of NF-κB promotes NSCLC tumorigenesis in mice and significantly correlates with advanced TNM stages and poor prognoses of NSCLC patients [13, 14] . Moreover, the NF-κB signaling pathway has been demonstrated to be associated with lung cancer initiation, invasion, and cancer stemness maintenance [15, 16] . Dopamine attenuates protein kinase A (PKA) activation that is initiated by downregulating the cellular level of cyclic AMP (cAMP). In addition, PKA upregulates the NF-κB pathway by phosphorylating p65 on serine 276 [17, 18] . Moreover, activation of DRD2 suppresses nuclear translocation of NF-κB in the intracerebral hemorrhage (ICH) mouse model [19] . However, the biological functions of DRD2 in NSCLC patients and regulation of the NF-κB signaling pathway are unclear.
In this study, we observed decreases in the expression of DRD2 in NSCLC tissues in comparison with adjacent normal lung tissues. Furthermore, DRD2 expression was negatively correlated with the tumor size, TNM status, and overall survival, suggesting that DRD2 is an independent risk factor for NSCLC prognosis. Disruption of DRD2 expression promoted the growth of NSCLC cell lines A549 and SK-MES-1, and induced the NF-κB signaling pathway. Furthermore, DRD2 overexpression in tumor cell lines not only blocked lipopolysaccharide (LPS)-induced NF-κB signals, cell proliferation, and tumor growth in vitro, but also dramatically inhibited murine xenograft tumorigenesis in vivo. In summary, our study demonstrated that DRD2 inhibits NSCLC cell growth by blocking the NF-κB signaling pathway both in vitro and in vivo, which further indicates that DRD2 is a potential therapeutic target in NSCLC.
Materials and Methods
Tissue specimens and clinical data A total of 113 primary NSCLC tissue specimens were obtained from patients who underwent lung surgery at Nanjing Chest Hospital (Nanjing, China). No cases had been subjected to preoperative chemotherapy. All cases were followed up for at least 3 years. This study was approved by the Institutional Review Board of Nanjing Chest Hospital. Written informed consent was obtained from all participants. The patient characteristics are listed in Table 1 .
Cell culture and establishment of stable cell lines
Human NSCLC lines A549 and SK-MES-1 were obtained from the American Type Culture Collection (ATCC) (Manassas, VA, USA). Cells were cultured in RPMI 1640 medium containing 10% fetal bovine serum (FBS) (Hyclone, Beijing, China).
For DRD2 knockdown, the sequences of human DRD2-targeting and negative control siRNAs were 5′-GCAGGATTCACTGTGACATAA-3′ (siD2/1), 5′-GGATTCACTGTGACATCTT-3′ (siD2/2), and 5′-GGGATCATGGGTGTCATCTAC-3′ (siNC). DNA oligonucleotides incorporating the short hairpin RNA (shRNA)-encoding sequences were synthesized by Shanghai GenePharma Co., Ltd. (Shanghai, China) and annealed into double strands by incubation in Annealing Buffer for RNA Oligos (Beyotime Institute of Biotechnology, Haimen, China). Following digestion with BamHI and EcoRI restriction endonucleases (TransGen Biotech Inc., Beijing, China), the double-stranded DNA molecules were inserted into the pGCSineo-GFP lentiviral vector. Successful insertion was confirmed by DNA sequencing. pGCSi-neo-GFP-DRD2-shRNA/NC-shRNA plasmid DNA and packaging vectors were transiently transfected into HEK293T cells (ATCC) using Lipofectamine 2000 ( Thermo Fisher Scientific, Carlsbad, CA), according to the manufacturer's instructions. At 48 h after transfection, supernatants containing lentiviral particles were collected and purified by ultracentrifugation at 70, 000 × g for 2 h at 4°C. For transduction, cultured cells were seeded into a six-well plate at a density of 1 × 10 5 cells/well and cultured for 24 h. Lentiviral particles encoding shRNAs targeting DRD2 or NC shRNA were added to the media of A549 and SK-MES-1 cells, followed by incubation for 24 h. After replacing the culture medium, the cells were incubated for a further 48 h prior to analyses.
To construct a DRD2-expressing plasmid, full length cDNA of the DRD2 gene was obtained by reverse transcription (forward primer: CGGGATCCATGGATCCACTGAATCTGTCCTG; reverse primer: CCCTCGAGTCAGCAGTGGAGGATCTTCAGGA) and cloned into the pcDNA3.1 (−) vector (Invitrogen). The DRD2 expression plasmid pCDNA3.1-DRD2 and blank vector were transfected into A549 and SK-MES-1 cells, followed by selection using 800 μg/ml neomycin for 21 days.
Western blotting was employed to detect DRD2 levels in all transfected cells to verify successful transfection.
RNA extraction and quantitative real-time-polymerase chain reaction (qRT-PCR) analysis
Total RNA was extracted from NSCLC cells using TRIzol® reagent (Invitrogen, Carlsbad, USA). Reversetranscribed cDNA was obtained with the Prime-Script® RT Reagent Kit (TAKARA Biotechnology, Dalian, China). qRT-PCR analyses were performed with LightCycler®480 SYBR Green I Master (Roche, Welwyn Garden, Swiss). The primer sequences were as follows:
Bcl-2 forward: GGTGGGGTCATGTGTGTGG; Bcl-2 reverse: CGGTTCAGGTACTCAGTCATCC; BclXL forward: GAGCTGGTGGTTGACTTTCTC; 
Immunohistochemical analysis
Clinical specimens and xenografted tumors were fixed in formalin and embedded in paraffin. Tissue sections were prepared for immunohistochemistry (IHC) staining. Briefly, the sections were deparaffinized using a series of graded ethanol solutions. Primary antibodies against DRD2 (Proteintech, Rosemont, IL) and p65 (Cell Signaling Technology, Danvers, MA) were applied overnight at 4°C. The procedure was followed by streptavidin-peroxidase treatment (ZS-BIO, Beijing China). Staining was developed with DAB chromogen (Boster, Wuhan, China). Finally, immunoreactivity was scored by the nuclear staining intensity as reported previously [20, 21] (on a scale of 0-3: negative = 0; weak = 1; moderate = 2; strong = 3) × the percentage of stained cells (positively recorded on an ordered categorical scale: 0 =zero; 1 = 1%-25%; 2 = 26%-50%; 3 = 51%-100%), which resulted in a scale of 0-9. Immunoreactivity was evaluated by a senior pathologist.
Dual luciferase reporter assay
Cignal Finder 10-Pathway Reporter Arrays (Qiagen) were employed to identify the potential pathway(s) regulated by DRD2 in NSCLC cells, following the manufacturer's instructions.
Cells were seeded on 24-well plates and cultured without antibiotics until 80% confluence. Then, NF-κB luciferase reporter (containing six NF-κB-binding sites) and internal control pRL-TK plasmids were transfected into the cells. After treating the cells as described, the luciferase activities of the cells were measured using a dual luciferase reporter assay kit (Promega). Reporter luciferase activity was normalized to renilla luciferase activity.
Cell viability assay and colony formation in soft agar
MTT assays were carried out as described previously [22] to examine the proliferation changes of NSCLC cells.
For colony formation in soft agar, 1 × 10 3 cells were resuspended as single cells in 0.35% agarose/RPMI 1640 containing 10% FBS on 0.7% agarose in the same medium in 6-well plates. Cells were incubated for 14 days, and then colonies were stained overnight with 0.5 mg/ml p-iodonitrotetrazolium violet (Sigma, St. Louis, MO). Colonies of >100 μm in diameter were counted.
Immunoprecipitation (IP), nuclear protein extraction, and western blot analysis
Immunoprecipitation assays were conducted as described previously [23] . Briefly, transfected cells were lysed in lysis buffer for 30 min, followed by centrifugation at 12, 000 × g for 20 min at 4°C to remove debris. The lysates were incubated with 1 μg anti-PKA-Cβ antibody (sc-904, Santa Cruz Biotechnology) for 24 h at 4°C, followed by precipitation of protein A/G-agarose beads. For nuclear protein extraction, cells were collected and solubilized with CelLytic™ NuCLEAR™ (Sigma), according to the manufacturer's instructions. Proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and then transferred onto a polyvinyldifluoridine membrane (Millipore, Darmstadt, Germany). The membranes were probed overnight with antibodies against DRD2, p65 (Proteintech,), p-p65 (ser276, 3037 and ser536, 3031; Cell Signaling Technology), or histone H3 (Cell Signaling Technology). An anti-β-actin antibody (Proteintech) was used for the loading control. Western blotting was visualized using an enhanced chemiluminescence kit (Pierce, Waltham, MA).
Chromatin immunoprecipitation (ChIP)
ChIP assays were performed using a ChIP assay kit (Millipore), according to the manufacturer's instructions. After nuclear extracts were isolated as described above, an antibody against p65 (3034, Cell Signaling Technology) was used to immunoprecipitate chromatin in nuclear fractions, whereas a nonspecific IgG antibody was used for the negative control. Immunoprecipitated DNA was analyzed by qRT-PCR using specific primers: TNF-α (forward: CCCTCCAGTTCTAGTTCTATC; reverse: GGGGAAAGAATCATTCAACCA). Measurements were made in triplicate. cAMP determination A total of 1 × 10 4 cells/well were seeded in 6-well plates and cultured without antibiotics until 80% confluence. Cells were then harvested for cAMP detection. cAMP levels were measured in total cell lysates using an enzyme immunoassay kit (Biomol, Heidelberg, Germany), according to the manufacturer's instructions.
Murine xenografts and IHC
All animal experiments were approved by the Animal Care and Use Committee of Nanjing Chest Hospital. Six-week-old male Athymic mice were housed in a specific pathogen-free facility. Stable A549 and parental cells were suspended in 40% Matrigel matrix (BD Biosciences)/PBS at a density of 1×10 7 cells/ ml. NSCLC cells ( 2×10 6 ) were injected subcutaneously into the flank region of nude mice using 1-3-cm 3 tuberculin syringes. For drug experiment, quinpirole (10 mg/kg) was administered to the mice by gavage every day for 5 weeks. The tumor size was measured every 3 days using a caliper, and tumor volume was calculated using the following equation: tumor volume (mm All animal experiments were approved by the Animal Care and Use Committee of Nanjing Chest Hospital. A549 cells were suspended in 40% Matrigel matrix/PBS at a density of 1×10 7 cells/ml. Six-weekold male athymic mice were housed in a specific pathogen-free facility. NSCLC cells ( 1×10 6 ) were injected subcutaneously into the flank region of nude mice using 1-3-cm 3 tuberculin syringes. Quinpirole (10 mg/ kg) was administered to the mice by gavage every day for 5 weeks. Tumor size and mouse body weight were measured every 3 days. Tumor size was measured by a caliper, and tumor volume was calculated using the following equation: tumor volume (mm Tumor tissues were collected at the end point, fixed in formalin and embedded in paraffin. Tissue sections were prepared for IHC staining. Briefly, the sections were deparaffinized using a series of graded ethanol solutions. A primary antibody against p65 (1:100 dilution) was applied overnight at 4°C. The procedure was followed by streptavidin-peroxidase treatment. Staining was developed with DAB chromogen. Finally, immunoreactivity was scored as the nuclear staining intensity (on a scale of 0-3: negative = 0; weak = 1; moderate = 2; strong = 3) × the percentage of stained cells (positively recorded on an ordered categorical scale: 0 = zero; 1 = 1%-25%; 2 = 26%-50%; 3 = 51%-100%), which resulted in a scale of 0-9. Immunoreactivity was evaluated by a senior pathologist.
Statistics analysis
The Student's t-test (two-tailed, parametric test for normal distribution) or Mann-Whitney U-test (non-parametric test for non-normal distribution) were performed as appropriate to compare intergroup differences after a distribution check. Adjustments for multiple comparisons were made using the false discovery rate.
Overall survival (OS) was analyzed by the Kaplan-Meier method and Log-rank test. The High DRD2 group was defined by an IHC value that was higher than that of the median of total NSCLC tumors, and the low DRD2 group was lower than the median value. SPSS software 19.0 version (SPSS Inc., Chicago, IL) and GraphPad Prism 6 (GraphPad Software, Inc, San Diego, CA) were used for statistical analysis. P<0.05 was considered as statistically significant.
Results

Decreased expression of DRD2 in NSCLC tumor cells negatively correlates with clinicopathological features
Previous studies have reported that activation of DRD2 signaling correlates with inhibition of lung cancer progression [6] . To further investigate the role of DRD2 in NSCLC, we first measured the expression of DRD2 in 113 specimens of NSCLC tissues. Among 90 paired clinical samples, 62 adenocarcinoma specimens showed reduced DRD2 mRNA expression (≥50%) compared with the adjacent normal tissues, and 11 adenocarcinoma specimens had increased DRD2 mRNA expression (≥50%) (Fig. 1A, top panel) . In the squamous cell carcinoma cohort (23 pairs), we observed lower DRD2 mRNA levels in 17 tumors (≥50%) and increased DRD2 mRNA levels in four tumors (≥50%; Fig. 1A, bottom panel) . To confirm the expression of DRD2, we detected DRDR2 protein expression in our specimens by IHC analysis (Fig. 1C) . As shown in Fig. 1B , 57 adenocarcinoma and 12 squamous cell carcinoma tissues had lower IHC scores than the paired normal tissues. Moreover, the relationship between DRD2 expression and clinicopathological features was analyzed ( 
Downregulated DRD2 expression promotes NSCLC cell growth in vitro
To determine the effect of DRD2 on tumor cell growth, two tumor cell lines were investigated using shRNA-mediated knockdown. DRD2 expression was downregulated in A549 (adenocarcinoma cell line) and SK-MES-1 (squamous carcinoma cell line) cells (Fig.  2A) . MTT assays showed that downregulated expression of DRD2 in A549 and SK-MES-1 cells promoted tumor cell growth and colony formation (Fig. 2B) . To verify the effect of DRD2 on NSCLC cell growth, we generated A549 and SK-MES-1 cells with stable expression of DRD2 (Fig. 2C) . MTT assays and colony formation in soft agar showed that ectopic DRD2 impaired NSCLC cell proliferation and colony formation (Fig. 2C and D) . Therefore, DRD2 may be a potential target to inhibit NSCLC tumor cell growth. 
DRD2 abrogates the NF-
DRD2 overexpression reduces NSCLC cell viability and growth by inhibiting the NF-κB signaling pathway
In the present study, we demonstrated that DRD2 inhibited the NF-κB signaling pathway, cancer cell viability, and tumor growth. However, it was unclear whether inhibition of NSCLC cell viability and growth by DRD2 was mediated through the NF-κB signaling pathway. LPS promotes cancer cell proliferation through the NF-κB signaling pathway [24, 25] . Thus, LPS was employed to induce activity of the NF-κB signaling pathway in NSCLC cells. LPStriggered NF-κB signal activation was abrogated by overexpression of DRD2 in NSCLC cells (Fig. 5A) . Similarly, we obtained the same results using the DRD2 overexpression approach. Expression of phosphorylated p65 was reduced in DRD2-overexpressing tumor cells in response to LPS stimulation (Fig. 5B) . Furthermore, DRD2 blocked LPS-triggered NSCLC cell proliferation and colony formation in MTT and colony formation assays, respectively ( Fig.  5C and D) . Taken together, these results suggest that DRD2 inhibits NSCLC cell viability and growth by inhibiting the overactivated NF-κB signaling pathway.
DRD2 activation correlates with NSCLC tumor progression in vivo
We found that DRD2 inhibited NSCLC tumor cell growth in the in vitro experiments, suggesting that DRD2 is a promising therapeutic target to inhibit tumor progression. To confirm the biological and therapeutic roles of DRD2 in vivo, a murine xenograft model was established. The tumor volume was significantly decreased in DRD2-overexpressing xenografted tumors after 3 weeks (Fig. 6A) . In addition, the tumor size and weight of the DRD2-overexpressing group was significantly smaller and lower than those of the control group (P=0.0234; Fig. 6B ). Furthermore, we observed decreases in phosphorylated nuclear p65 (Fig. 6C ) and mRNA levels of Bcl-2 and TNF-α in DRD2-overexpressing xenografts (Fig. 6D) . Here, we also employed quinpirole (a selective DRD2 agonist) to treat NSCLC- 
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Cellular Physiology and Biochemistry xenografted mice. As shown in Fig.7 A-D, the activation of DRD2 by quinpirole abrogated NSCLC xenograft growth and NF-κB signal. The drug treatment has no effect on mice, livers, hearts and spleens weight ( Fig.7 E and F) . Next, we investigated the correlation of DRD2 expression and patient OS. Kaplan-Meier analysis and Log-rank tests demonstrated that patients with higher DRD2 expression had a significantly higher OS rate than patients with lower DRD2 expression (P=0.0178; Fig. 6E ). Taken together, these results clarified that DRD2 inhibited NSCLC cell tumorigenicity through inhibiting the NF-κB signaling pathway, suggesting that DRD2 is a potential therapeutic target for NSCLC immunotherapies.
Discussion
Lung cancer is a frequently diagnosed cancer and NSCLC is the leading cause of lung cancer mortality [26] . Currently, increasing numbers of patients do not respond to traditional chemotherapies and radiotherapy, leading to a poor prognosis and low survival rate [27] . Since the rapid development of immunotherapy, such therapies have been implicated in curing recurrent diseases [28] . Thus, studies should investigate the underlying mechanisms in NSCLC.
Current studies have shown contradictory roles of DRD2 in various solid tumors. Previous reports have demonstrated DRD2 overexpression in breast cancer and esophageal squamous cell carcinoma. Overexpression of the DRD2 gene is significantly associated with the progression of these tumors [29, 30] . Polymorphisms responsible for reduced DRD2 expression are not only associated with the risk of developing colorectal cancer, but also an increased risk of recurrence of advanced colorectal adenoma [31, 32] . The polymorphisms of DRD2 resulting in lower dopamine bioavailability are associated with an increased risk of developing NSCLC [33] . In the present study, downregulated expression of DRD2 was found in adenocarcinoma and squamous cell carcinoma, the two major histological types of our NSCLC specimens. DRD2 overexpression inhibited A549 tumor growth and NF-κB signaling in vivo, which is consistent with a previous report [6] . Although adenocarcinoma and squamous cell carcinoma have different biological characters [34] , we clarified that DRD2 inhibited the NF-κB signaling pathway through the DRD2/PKA axis in both adenocarcinoma (A549) and squamous cell carcinoma (SK-MES-1) cell lines. These results suggest that DRD2 affects NSCLC cellular functions, and targeting DRD2 may be a promising therapeutic strategy for adenocarcinoma and squamous cell carcinoma.
DRD2 agonists have been shown to inhibit lung cancer progression by reducing angiogenesis and tumor-infiltrating myeloid-derived suppressor cells in mice [6] . In Fig. 7 , we employed quinpirole to treat NSCLC-xenografted mice. Our data confirmed that quinpirole treatment inhibited NSCLC-xenografted tumor growth and the NF-κB signaling pathway in vivo. The treatment had no effects on the weights of the murine body, liver, heart, or spleen. The above data suggest that quinpirole is a promising and safe drug for NSCLC treatment.
In NSCLC cells, overexpression of DRD2 abrogated cellular cAMP and phosphorylation of p65. PKA is required for phosphorylation of p65 at serine 276 [18] . Both phosphorylations of p65 at serine 276 and 536 were inhibited in DRD2-overexpressing NSCLC cells. Because of the crosstalk of NF-κB signaling pathways [12] , we hypothesized that phosphorylation of p65 at serine 276 may promote phosphorylation at serine 536 in NSCLC cells. In the ICH mouse model, activation of DRD2 inhibits NF-κB nuclear translocation by αB-crystalline [19] . We suggest that overexpressed DRD2 also blocks NF-κB nuclear translocation in NSCLC cells. However, the change in NF-κB nuclear translocation was caused by disruption of p65 phosphorylation, and a different mechanism may be caused by the discriminating system.
In melanoma, β3-adrenergic receptor, another G protein-coupled receptor, mediates the response of tumor cells to the tumor microenvironment, such as hypoxia and ischemia, to enhance melanoma through fibroblasts crosstalk [35] . Phosphorylation at serine 536 plays a pivotal role in regulating p65 nuclear translocation, and serine 276 is required for recruitment of CREB-binding protein/p300 to p65 for activated transcription [36] . Because DRD2 blocks LPS-induced p65 phosphorylation, the above evidence indicates that DRD2 may abrogate inflammatory stimuli in the microenvironment of NSCLC cells and inhibit cancer cell proliferation. Taken together, we identified that DRD2 inhibits NSCLC cell growth by inhibiting the NF-κB signaling pathway, suggesting a critical role of DRD2 in the development of NSCLC, which further indicates that DRD2 could be a promising immunotherapeutic target in NSCLC.
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